The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 2, 2007, Pages 156-162

  Wendland, Merideth M M ^a   Smith, David C ^a   Boucher, Kenneth M ^a   Asch, Julie D ^b   Pulsipher, Michael A ^b   Thomson, John W ^c   Shrieve, Dennis C ^a   Gaffney, David K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c LDS HOSPITAL   (United States)

Author keywords

Hematopoietic progenitor cell transplant; High dose chemotherapy; Involved field radiation therapy; Non Hodgkin lymphoma

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34147135138     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000251242.32763.35     Document Type: Article

References (26)

1. Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991;9:25-38.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
3. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
4. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22:3032-3038.
5. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130:363-372.
6. Wheeler C, Strawderman M, Ayash L, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993;11:1085-1091.
7. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
8. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10:116-127.
9. Mabed M, Al-Kgodary T. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas. Bone Marrow Transplant. 2006;37:739-743.
10. Sora F, Piccirillo N, Chiusolo P, et al. Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation: a salvage regimen for patients with refractory or recurrent non-Hodgkin lymphoma. Cancer. 2006;106:859-866.
11. Aviles A, Delgado S, Nambo MJ, et al. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys. 1994;30:799-803.
12. Takvorian T, Canellos GP, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987;316:1499-1505.
13. Mundt AJ, Williams SF, Hallahan D. High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy. Int J Radiat Oncol Biol Phys. 1997;39:617-625.
14. Rapoport AP, Lifton R, Constine LS, et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant. 1997;19:883-890.
15. Friedberg JW, Neuberg D, Monson E, et al. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2001;7:446-453.
16. Toren A, Nagler R, Nagler A. Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities. Med Oncol. 1998;15:113-118.
17. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
18. Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc. 1972;135:185-207.
21. Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004;22:2826-2834.
22. Dawson LA, Saito NG, Ratanatharathorn V, et al. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2004;59:208-218.
23. Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med. 1988;318:1028-1032.
24. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993;85:1932-1937.
25. Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
26. Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:2208-2214.